Chief Executive Officer
Director Investor Relations & Corporate Communications
Rob Koremans, qualified as Medical Doctor from RSM Erasmus University in the Netherlands and Executive MBA in US, has over 30 years’ experience in managerial and executive roles, gained mainly in the pharmaceutical industry at various international companies.
In 1988 he started his professional career at Sanofi in the Netherlands as Product Manager, then being appointed as Head of Cardiovascular Unit.
In 1990, he joined Excerpta Medica Medical Communications, part of Elsevier Group, as International Business Development Director. After one year experience as Marketing & Service Manager at J&J Cilag International in Switzerland, in 1993 he joined Serono Group where he covered different positions with growing responsibilities: he was first General Manager at Ares-Serono in the Netherlands, then Managing Director at Serono Germany and finally Vice President Europe based in Switzerland.
In 2000, he joined Grunenthal as Head of Area Management Europe & USA and Head of Global Marketing, being then appointed Member of the Executive Board.
In 2007, he became Chief Executive Officer and co-owner at Cryo-Save Group, Europe’s leading stem cell storage company; two years later, he was appointed as President and CEO of Zentiva, part of the Sanofi-Aventis Group, in Czech Republic.
In 2012, he joined Teva Pharmaceutical Industries (TPI) as Member of TPI Executive Committee and President & CEO of Teva Pharmaceuticals Europe, then becoming President & CEO Global Specialty Medicines. Finally, in 2018 he joined Nutreco, global leader in animal nutrition, aqua culture and alternative proteins, as Chief Executive Officer.
In December 2021 he joined Recordati as Chief Executive Officer.
Alberto Martinez has a PhD in Pharmacy and an Executive MBA with about twenty years of experience in the pharmaceutical industry.
After the initial activity as Sales Representative and Product Manager at Janssen, in 2003 he joined Mundipharma, where he covered different positions with growing responsibilities both at local and European level: he started his professional path as European Product Manager becoming, in 2006, European Marketing Manager.
One year later he was appointed General Manager at Mundipharma Spain, then widening his responsibilities to Portugal, As of 2014, he was at the same time Managing Director at Napp Pharmaceuticals in UK and Regional Director Northern Europe Mundipahrma.
In 2016, he was appointed European Director Commercial Operations and finally, one year later, President and Chief Executive Officer Europe, with global responsibility including R&D, manufacturing and supply chain.
In January 2021 he joined Recordati as Executive Vice President Specialty and Primary Care Business Unit.
Gabriele Finzi holds a degree in Business Administration with major in Corporate Finance from the Bocconi University (Milan). After an initial experience in investment banking, he began his corporate career as an M&A Analyst at Barilla, where he took part in a number of deals.
In 2005, he joined Siemens Italy to set up the local M&A department; subsequently he became responsible for the financial planning of the South West Europe region of Siemens Medical Solutions.
In 2008 he joined the Corporate Development department at Recordati where he has been assigned increasing responsibilities and has completed several acquisitions; he was appointed Group Business Development Director in 2012, Vice President Corporate Development in 2016 and Vice President Corporate Development & Licensing in 2019.
Since 2022 he takes the responsibility also for the Innovation activities of the Group, in the role of Executive Vice President Corporate Development, Licensing & Innovation.
Roberto Teruzzi, who holds a degree in veterinary medicine and two international MBAs, has thirty years of experience in managerial roles in the pharmaceutical business.
In 1986 he started his professional career in Boehringer Mannheim, in R&D and then in Commercial area. He covered different roles with growing responsibilities in various pharmaceutical companies: as of 1989 he was International Product Manager at Farmitalia Carlo Erba, in 1992 he moved to Zambon as Business Development Manager and in 1994 he joined Pharmacia & Upjohn as International Markets Manager.
In 1998 he was in charge of establishing the Italian subsidiary of Ratiopharm, becoming Managing Director of the Company. In 2005 he moved to Alliance Boots, where he established the Almus and Alvita Companies, for the commercialization of generics and para-pharmaceutical products in South Europe, becoming General Manager Europe Almus & Alvita and Managing Director of Almus Italy and Alvita Italy.
In 2008 he joined Mipharm as Chief Operating Officer, responsible for Commercial, Logistics, Distribution and R&D activities; after the transfer of commercial activities to Novartis he was in charge of the production plant, with main responsibility of maximizing profitability.
Finally, in 2010, he moved to Corvette Group (acquired by Recipharm in 2014) as Chief Executive Officer to coordinate Biologici Italia Laboratories, Edmond Pharma and Liosintex, companies operating in third parties manufacturing and development of pharmaceutical products as well as in commercial activities.
In April 2015 he joined Recordati as Executive Vice President of Group Industrial Operations.
Federica De Medici has a degree in Economics and Business from the Università degli Studi di Pavia and has spent more than twenty years in Investor Relations, both in Advisory firms and in listed companies.
In 1997 she started her professional career as Audit Consultant at KPMG, then becoming Senior Consultant in Transaction Service Department, focused on M&A. In 2000, she started her path in Investor Relations in Barabino & Partners, consulting firm specialized in Investor Relations and Financial Communication, as Advisor to Italian listed companies on IR plans supporting IPO’s, takeovers bids, capital increases.
In 2003, she joined RCS MediaGroup where she covered different positions with growing responsibility: she was first, Head of Investor Relations, in charge of the setup and the development of the related department, then Digital Strategy and Intelligence Director and finally Group Investor Relations Director.
In 2016 she moved to Wind Tre as Group Investor Relations Director, in charge of fostering the relationship with investor community, financial markets and rating agencies, and taking later on also the responsibility of the Business Intelligence and Market Research Department.
In October 2020 she joined Recordati as Director Investor Relations & Corporate Communications.
Laura Conti is a graduate in foreign languages and literature from Università Cattolica del Sacro Cuore in Milan. She has two post-degree masters, one in business communications and one in journalism.
Laura has more than 20 years of experience in listed companies and international environments and has dealt with almost all aspects of corporate communication, internal and external: from wide-reaching organizational projects to company rebranding and cultural change. She has worked in a range of different industries, including banking, hospitality, digital payments, and e-learning.
Laura joined Recordati in 2022 as Group Internal Communications Director, with the responsibility of designing and executing the internal and digital communications strategy of the company. She reports directly to the CEO.
Passionate about humanitarian aid efforts, Laura is also an active volunteer for the Italian Red Cross.
Angelo Siciliano has more than 15 years’ experience across different industrial sectors and geographies.
He joined Recordati in 2015 as Responsible of Corporate Organizational Development, after working in management consulting on various global positions.
He previously held a range of operational roles at Fiat Research Center, Dallara Automobiles, Maserati Racing Team and Italcementi, before moving to Accenture where he developed expertise in running PMI, global transformation and operational excellence programs in Roche, GSK and other multinational companies from non-pharma sectors.
Angelo gained a master’s degree in mechanical engineering with specializations in automotive design and biomechanics and a master in production management at Polytechnic University of Milan.
Since 2014 Angelo is certified master black belt in Lean Manufacturing.
Maria Lamelas graduated in Political Economics and obtained a Master Degree in Econometrics. She brings 20+ years of working experience in different sectors. She started working as an Economist for the Italian Government while teaching economics at University. After some years, she joint Spencer Stuart, a multinational consulting company in the Executive Search, where she worked for 10 years in assignments across Europe. In 2017 she joint Webuild, a multinational player in the infrastructure industry, growing fast through acquisitions. She grew in the Global Human Resources up to her last position as for the Group and VP HR for their Subsidiary US. She has been a key player in their cultural and organizational transformation process.
She joined Recordati in 2023 as People Engagement and Change Management Director, supporting the group’s cultural evolution.
INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003
The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.
In any event we assure you that your data will be processed solely for the above purposes and using the above methods.
The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.
A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).
Requests must be sent to the Data Processor of Recordati:
by email, to the address: ;
or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.
In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.
Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.